{
    "organizations": [],
    "uuid": "a6c1071c64dade226c1a1f63eefc8ac1ba18c4de",
    "author": "",
    "url": "https://www.reuters.com/article/brief-johnson-johnsons-unit-actelion-sub/brief-johnson-johnsons-unit-actelion-submits-supplemental-new-drug-application-to-u-s-fda-seeking-approval-of-opsumit-idUSASC09Y85",
    "ord_in_thread": 0,
    "title": "BRIEF-Johnson & Johnson's Unit Actelion Submits Supplemental New Drug Application To U.S. FDA Seeking Approval Of Opsumit",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30, 2018 / 1:20 PM / Updated 17 minutes ago BRIEF-Johnson & Johnson's Unit Actelion Submits Supplemental New Drug Application To U.S. FDA Seeking Approval Of Opsumit Reuters Staff 1 Min Read\n Johnson & Johnson:\n* ACTELION SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FDA SEEKING APPROVAL OF OPSUMITÂ® (MACITENTAN) FOR THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)\n* ACTELION PHARMACEUTICALS SAYS SUBMITS SUPPLEMENTAL NDA TO FDA FOR APPROVAL OF OPSUMIT (MACITENTAN) FOR TREATING CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION Source text for Eikon: Further company coverage:",
    "published": "2018-04-30T16:17:00.000+03:00",
    "crawled": "2018-04-30T16:23:44.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "johnson",
        "unit",
        "actelion",
        "submits",
        "supplemental",
        "new",
        "drug",
        "application",
        "fda",
        "seeking",
        "approval",
        "opsumit",
        "reuters",
        "staff",
        "min",
        "read",
        "johnson",
        "johnson",
        "actelion",
        "submits",
        "supplemental",
        "new",
        "drug",
        "application",
        "fda",
        "seeking",
        "approval",
        "macitentan",
        "treatment",
        "chronic",
        "thromboembolic",
        "pulmonary",
        "hypertension",
        "cteph",
        "actelion",
        "pharmaceutical",
        "say",
        "submits",
        "supplemental",
        "nda",
        "fda",
        "approval",
        "opsumit",
        "macitentan",
        "treating",
        "chronic",
        "thromboembolic",
        "pulmonary",
        "hypertension",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}